Clinical Trials Logo

Chloasma clinical trials

View clinical trials related to Chloasma.

Filter by:
  • None
  • Page 1

NCT ID: NCT03618277 Withdrawn - Chloasma Clinical Trials

Identification of Biomarkers and Characterization of Melasma

Start date: October 10, 2018
Phase: N/A
Study type: Interventional

Melasma (also called chloasma and pregnancy mask) is characterized by pigmented lesions darker than their usual complexion on the faces of affected subjects. The physiopathology of melasma is still poorly understood. To date, the factors that favor the onset of melasma appear to be: genetic predisposing factors, changes in sex hormone levels, and sun exposure. Vascularization as well as elastosis also appear to be increased in skin with melasma. The aim of this study is to evaluate the different levels of expression of biomarkers between pigmented melasma lesions and surrounding healthy skin when melasma is highly pigmented but also when it is dormant (ie treated melasma, without UV solicitation in the heart of winter). The goal is to identify and better understand the involvement of different genes and proteins and thus offer more specific ways of care, and therefore effective, for the subjects.

NCT ID: NCT03585179 Not yet recruiting - Melasma Clinical Trials

Oral and Topical Tranexamic Acid for the Treatment of Melasma

TRANEXAMICO
Start date: August 1, 2018
Phase: Phase 3
Study type: Interventional

Tranexamic acid has been used for treating melasma due to its effect on decreasing the activity of tyrosinase and melanogenesis. This 3-arm clinical trial will asess the efficacy and safety of oral and topical tranexamic acid as monotherapy compared with topical hydroquinone for 12 weeks in adults with melasma. The primary outcome will be the percentage of reduction at 12-week period of mMASI and melanin index. The incidence of adverse effects will be reported at weeks 4, 8 and 12.